tradingkey.logo
tradingkey.logo

Quantum Biopharma Announces Appointment Of Principal Investigator For Planned Phase 2 Clinical Trial Of Lucid-21-302 (Lucid-MS) In Multiple Sclerosis

ReutersMar 26, 2026 12:59 PM

Quantum Biopharma Ltd QNTM.CD:

  • QUANTUM BIOPHARMA ANNOUNCES APPOINTMENT OF PRINCIPAL INVESTIGATOR FOR PLANNED PHASE 2 CLINICAL TRIAL OF LUCID-21-302 (LUCID-MS) IN MULTIPLE SCLEROSIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI